Member Info for Howzaty

Re "see my link". So given the March date on the document one could be forgiven for asking what on earth is the delay has been about?

MDx you are seemingly well wide of the mark with respect to the ct infectivity boundary threshold which is acknowledged to be around ct 27 accepting that correlation of infectivity and ct value is an approximation. Comment?

"emphasis on ct number ..." this gibberish seems to conflict somewhat with the infectious boundary threshold put forward and evidenced by Avacta and presented by Al.

ppredicated...

I think we are going to have to wait for a) home use b) first seriously large order, to get the jumps into the blue we all want. The good news is that both are within shouting distance I suspect. Could be however, that b) is pedicated on a).

My conclusion, for what it's worth, is that alot is hanging on Medusa19 achieving self test for AffiDx. When that drops my feeling is there will be a cascade of communications. But it has been a loooong wait. GLA.

The 60% figure confirms to me we are governed by cretins or folk on the receiving end of brown envelopes. So entry to an event is by LFT result, I opt for an Avacta LFT at 100% sensitivity across the infectious range whereas you opt for a 60% LFT. We both have negative results but you have Covid and end up sitting next to me. Thanks Boris. Why not drop it to 50% and sort it with a coin toss is my suggestion to the Prime Moron.

I feel everyone needs to lighten up on perceived deadlines. The programme dates Avacta provides are as Al has explained necessarily indicative because many factors are beyond Avactas direct control. This is just a fact of life. Some will choose to exploit 'missed deadlines' for their own advantage, fact is all dates are indicative and the alternative would be to have no information at all. So my advice is not to get too excited about deadlines. As I say to my kids if you can't influence an outcome its pointless expending energy worrying about it.

Thats really very interesting. Just thinking about all those vats of Affimers does it for me.

I think initially some companies may take a fairly relaxed view about testing but once they experience whole offices/ buildings unoccupied because people are off sick their views will change.

"... Commisioned large scale ..."
Q20: Is Avacta looking to expand its clinical data sets beyond those already announced?

We are carrying out additional validation studies to build larger data sets and strengthen the statistical analysis.

Was going to say "losing money hurts" is only true if you have sold. We have bought into a business, shortly news will arrive and all indications are that this will be extremely positive if so boom through 300p and away. Had to drop before hitting the much discussed highs. But in my opinion these will come. Only thing to do is keep the faith if one bought at recent highs, the research has been done.

"Losing mney hurts

I think it was Warren Buffett who likend buying shares to buying a farm. This farm is a gem, virdant acres bursting with potential, a keeper not for selling on. Not at any price, well any price short of 25 pounds a share any hoo.

Yuk! Its a thing of beauty. mushrooms cooked in butter, cheese topping toasted undercthe grill. Mmmmmmm.

Now thats what happens when you're looking at your tablet and cooking an omelette at the same time, well ish. Cheese and mushroom if you were wondering.

Just to say the Bioserve AffiDX Description does state "routine monitoring of emerging varients" or similar.

The Bioserve AffiDX Description does state routine monitoring of emerging varients.

It may have been said already but perhaps Avacta should provide the Chinese manufacturer with the option of using its Affimers.

For what its worth here's my view. I like many bought this share on the back of a detailed analysis. I bought not in the hope of achieving 100% but 10 times that, call me greedy if you like. Covid has served to establish the AffiDX brand and Avacta is at this moment pursuing an addressable market of around 8 billion dollars through discussions with various majors who may adopt Affimers in their tests, nothing to do with Covid. Lets imagine half of those come to fruition, suddently Avacta is earning a conservative 200 million dollars per annum each and every year for the forseeable future. In comparison a one-off Covid (not forgetting all the misery Covid has caused) bonansa is not that significant. I would be happy with 60m this year, a couple of years cash burn. This is but one smallish part of the Avacta story. They can take this to 100p but I wont be selling any this side of 10 pounds and for the most part I will be holding untill 25. Avacta is a major company in the making and shareholders have a chance to be part of the story. No gain without pain as they say. All in my own opinion and not advice but I'm very much on the same page as Al regarding how big this company is going to get. Now you may know of a better investment, but I dont. Just, in the words of the song, "need a little patience" and for your own sanity to stop looking at the share price ever day. Oh one other thing , I dont think its very smart to short this baby. Good luck all.